Clinical studies demonstrate that compounded GLP-1 injections achieve comparable weight loss and blood sugar reduction when dosed appropriatelypatients lose an average of 1222% of body weight over six months, matching published brand-name trial outcomes
We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity
But still others lamented the disappearance of the muscular body she once defended, and suspected that she was reshaping herself, and her brand, to fit into that conventional mold
At the same time, gross spending increased ninefold, from about $1 billion in 2019 to almost $9 billion in 2024, and gross spending per GLP-1 prescription reached $1,000 in 2024